After the discovery that levodopa is absorbed by beta cells in the human pancreas and synthesizes dopamine (11), numerous studies have revealed that dopamine is co-secreted with insulin and can negatively regulate glucose-stimulated insulin secretion (GSIS), proving its potential role as a therapeutic target for type 2 diabetes (12–14). The gene discussed is INS; the disease is type 2 diabetes mellitus.